Art and neurology have long been intertwined. Renaissance artwork depicted the nuances of human anatomy and pathology with ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

Among patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor use was linked to reduced risk for neurodegenerative disorders. Sodium-glucose cotransporter 2 (SGLT2) inhibitor use is ...

Diabetes describes a group of metabolic diseases characterized by high blood sugar levels. Diabetes can be caused by the pancreas not producing insulin (type 1 diabetes) or by insulin resistance ...

People with Type 2 diabetes generally have a tendency to get more tired and ... When one is dehydrated, naturally one feels very tired. Certain medicines like SGLT2 inhibitors, (e.g., Dapagliflozin, ...

Among patients with type 2 diabetes, sodium-glucose cotransporter 2 inhibitor use was linked to reduced risk for neurodegenerative disorders. Sodium-glucose cotransporter 2 (SGLT2) inhibitor use ...

A RECENT real-world study has found that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are more effective at reducing kidney complications in ...

and sodium glucose cotransporter 2 (SGLT2) inhibitors among individuals with type 1 diabetes (T1D), according to a research letter published online October 23 in the Journal of the American ...

Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an SGLT2 inhibitor ... Subgroups, including by diabetes mellitus and ...

MONDAY, Oct. 28, 2024 (HealthDay News) — From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose cotransporter 2 (SGLT2) ...

Differentiating between an irrational versus a rational fear of hypoglycemia has treatment implications and presents significant challenge for clinicians facing patients with type 1 diabetes ... Do ...